OTCMKTS:CLPBY Coloplast A/S (CLPBY) Stock Price, News & Analysis $6.49 +0.04 (+0.66%) As of 12:26 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesInsider TradesSEC FilingsShort InterestBuy This Stock About Coloplast A/S Stock (OTCMKTS:CLPBY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coloplast A/S alerts:Sign Up Key Stats Today's Range$6.39▼$6.5950-Day Range$6.13▼$7.1252-Week Range$6.10▼$10.03Volume174,534 shsAverage Volume581,116 shsMarket Capitalization$14.63 billionP/E Ratio46.38Dividend Yield5.39%Price TargetN/AConsensus RatingReduce Company Overview Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments. In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste. The continence care segment offers catheters, drainage bags and related supplies for individuals with bladder control issues. The company’s wound and skin care portfolio includes advanced dressings, negative-pressure wound therapy and pressure ulcer prevention products, while its interventional urology line features devices for minimally invasive procedures and diagnostics in urological conditions. Founded in 1957 by Danish entrepreneur Aage Louis-Hansen, Coloplast began when Louis-Hansen developed the first adhesive ostomy bag to help his wife manage her postoperative care. Since then, the company has grown from a small family operation into a publicly listed corporation on the Copenhagen Stock Exchange, with an American depositary receipt program trading under the symbol CLPBY in the U.S. The company is led by President and CEO Peter Clemmensen, who has overseen continued expansion of R&D and manufacturing capabilities. Headquartered in Humlebæk, Denmark, Coloplast operates manufacturing and research facilities across Europe and North America, supported by a global sales and distribution network. Its products are available in more than 100 countries, with regional offices and partnerships that ensure local market support and training for healthcare professionals. The company places a strong emphasis on customer proximity and collaborative development to address the evolving needs of patients and clinicians worldwide.AI Generated. May Contain Errors. Read More Coloplast A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCLPBY MarketRank™: Coloplast A/S scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingColoplast A/S has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageColoplast A/S has only been the subject of 1 research reports in the past 90 days.Read more about Coloplast A/S's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.50% Earnings GrowthEarnings for Coloplast A/S are expected to grow by 7.50% in the coming year, from $0.40 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coloplast A/S is 46.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.52.Price to Earnings Ratio vs. SectorThe P/E ratio of Coloplast A/S is 46.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.78.Price to Earnings Growth RatioColoplast A/S has a PEG Ratio of 1.99. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioColoplast A/S has a P/B Ratio of 6.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Coloplast A/S has been sold short.Short Interest Ratio / Days to CoverColoplast A/S has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Coloplast A/S has recently decreased by 34.37%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipColoplast A/S is a leading dividend payer. It pays a dividend yield of 5.59%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthColoplast A/S does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Coloplast A/S is 250.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on EPS estimates, Coloplast A/S will have a dividend payout ratio of 81.40% in the coming year. This indicates that Coloplast A/S may not be able to sustain their current dividend.Read more about Coloplast A/S's dividend. News and Social Media2.2 / 5News Sentiment0.45 News SentimentColoplast A/S has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Coloplast A/S this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CLPBY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Coloplast A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coloplast A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsColoplast A/S has minimal institutional ownership at this time.Read more about Coloplast A/S's insider trading history. Receive CLPBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coloplast A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLPBY Stock News HeadlinesColoplast A/S Sponsored ADR (OTCMKTS:CLPBY) Sees Large Drop in Short InterestMay 20 at 3:41 AM | americanbankingnews.comColoplast: Went 'BUY' A Bit EarlyMay 16, 2026 | seekingalpha.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 21 at 1:00 AM | American Alternative (Ad)Coloplast: The Market Is Throwing Away A High-Quality CompounderMarch 17, 2026 | seekingalpha.comColoplast appoints Gavin Wood as new CEOMarch 4, 2026 | globenewswire.comColoplast A/S - Updated Financial Calendar 2025-26February 11, 2026 | globenewswire.comColoplast A/S (CLPBY) Q1 2026 Earnings Call TranscriptFebruary 6, 2026 | seekingalpha.comColoplast A/S - Interim Financial Report, Q1 2025/26February 6, 2026 | globenewswire.comSee More Headlines CLPBY Stock Analysis - Frequently Asked Questions How have CLPBY shares performed this year? Coloplast A/S's stock was trading at $8.50 on January 1st, 2026. Since then, CLPBY shares have decreased by 23.6% and is now trading at $6.4925. How were Coloplast A/S's earnings last quarter? Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) released its earnings results on Tuesday, May, 12th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a trailing twelve-month return on equity of 31.96% and a net margin of 7.46%. How do I buy shares of Coloplast A/S? Shares of CLPBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today5/21/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED INSTRUMENTS Sub-IndustryN/A Current SymbolOTCMKTS:CLPBY Previous SymbolNASDAQ:CLPBY CIK1294325 Webwww.coloplast.com Phone(454) 911-1111FaxN/AEmployees17,156Year Founded1957Profitability EPS (Trailing Twelve Months)$0.14 Trailing P/E Ratio46.38 Forward P/E Ratio16.23 P/E Growth1.99Net Income$538.49 million Net Margins7.46% Pretax Margin22.22% Return on Equity31.96% Return on Assets10.20% Debt Debt-to-Equity Ratio1.50 Current Ratio1.30 Quick Ratio0.81 Sales & Book Value Annual Sales$4.13 billion Price / Sales3.54 Cash Flow$0.37 per share Price / Cash Flow17.54 Book Value$1.06 per share Price / Book6.13Miscellaneous Outstanding Shares2,253,670,000Free FloatN/AMarket Cap$14.63 billion OptionableNot Optionable Beta0.15 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:CLPBY) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coloplast A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Coloplast A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.